- Updated: Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults (5/15/23)
- Topics, Trends & Updates for May (5/11/23)
- Updated: Second-Line ART After Treatment Failure or for Regimen Simplification (5/10/23)
- Updated: Immunizations recommendations -- MenB (5/9/23)
- Updated: Guidance: Addressing the Needs of Older Patients in HIV Care (5/5/23)
- Updated: ART Drug-Drug Interactions with lenacapavir (LEN) (4/26/23)
- Updated: Immunizations recommendations -- MenB, HBV, pneumococcal, and zoster (4/18/23)
- Topics, Trends & Updates for March (3/9/23)
- Updated: Substance Use Harm Reduction in Medical Care (2/28/23)
- Updated: Rapid ART Initiation (2/9/23)
- Updated: Second-Line ART After Treatment Failure or for Regimen Simplification (1/19/23)
- Topics, Trends & Updates for January (1/12/23)
- Updated: Immunizations for Adults With HIV (12/15/22)
- Topics, Trends & Updates for December (12/2/22)
- New Guideline: Second-Line ART After Treatment Failure or for Regimen Simplification (11/29/22)
- Topics, Trends & Updates for November (11/10/22)
- Updated: Prevention and Management of HPV Infection in Adults With HIV (11/4/22)
- Updated: ART Drug-Drug Interactions (10/17/22)
- Topics, Trends & Updates for October (10/13/22)
- New Guideline: HCV Screening, Testing, and Diagnosis in Adults (10/6/22)
- New Guideline: Pretreatment Assessment in Adults With Chronic HCV Infection (10/6/22)
- New Guideline: Treatment of Chronic HCV Infection in Adults (10/6/22)
- Updated: Pneumococcal Vaccine Recommendations for Adults With HIV (10/5/22)
- Updated: NYS Good Practices in Managing Infant Perinatal HIV Exposure (9/19/22)
- Updated: HIV Testing During Pregnancy, at Delivery, and Postpartum (9/12/22)
- FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults (5/25/23)
- NYSDOH AI Dear Colleague Letter: New York State’s continued response to mpox (5/19/23)
- NYSDOH AI Health Advisory: Mpox Cases Associated with Person-to-Person Transmission (5/2/23)
- NYSDOH & NYCDOHMH Launch Mpox Vaccine Campaigns Urging Eligible New Yorkers to Prepare Now for a Healthy Summer (5/2/23)
- NYCDOHMH Dear Colleague: COVID-19 Vaccination Updates (4/21/23)
- FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines (4/18/23)
- NYSDOH AI & NYCDOHMH Mpox Dear Colleague Letter Announcing Spring and Summer Media Campaign (3/27/23)
- FDA Authorizes Bivalent Pfizer-BioNTech COVID-19 Vaccine as Booster Dose for Certain Children 6 Months through 4 Years of Age (3/14/23)
- FDA Authorizes First Over-the-Counter At-Home Test to Detect Both Influenza and COVID-19 Viruses (2/27/23)
- NYCDOHMH: Bivalent COVID-19 Vaccines for Children Ages 6 Months Through 5 Years (12/14/22)
- FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age (12/8/22)
- NYSDOH Statement on Mpox Name Change (12/1/22)
- WHO Recommends New Name for Monkeypox Disease (11/30/22)
- NYCDOHMH: Novavax COVID-19 Boosters Allowed for People Ages 18 Years and Older (11/1/22)
- NYCDOHMH: Considerations for Monkeypox and Pregnant, Recently Pregnant, and Breastfeeding Patients (10/19/22)
- NYCDOHMH: Bivalent COVID-19 Booster Recommendation Expanded to Include Children Ages 5 to 11 Years (10/15/22)
- New NYS Regulation: Minor Consent Allowed for Monkeypox Services (10/14/22)
- FDA Authorizes Moderna and Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose in Younger Age Groups (10/12/2022)
- NYSDOH AI Dear Colleague Letter: COVID-19 Prevention & Treatment for Patients with HIV: Vaccines and Nirmatrelvir/Ritonavir (Paxlovid) (10/11/22)
- CDC: Severe Manifestations of Monkeypox among People who are Immunocompromised Due to HIV or Other Conditions (9/30/22)
- NYCDOHMH: Bivalent COVID-19 Boosters Recommended for Everyone Ages 12 Years and Older (9/17/22)
- FDA Takes Significant Action to Help Expand Access to Testing (9/7/22)
- HIVinfo: Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children (9/6/22)
- NYCDOHMH: Considerations for Monkeypox Testing of Pediatric Patients (9/1/22)
- FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose (8/31/22)
- NYSDOH AI: Call for Abstracts: 2023 Ending the Epidemic Summit & World AIDS Day Events (6/1/23)
- FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder (5/23/23)
- NYS Medicaid Update Special Edition – Part Four: NYRx Pharmacy Benefit Transition (5/23/23)
- CEI Newsletter (5/23/23)
- AETC NCRC: May 2023 Monthly Update (5/17/23)
- NYSDOH AI Dear Colleague Letter: Transition of pharmacy benefits in the New York State Medicaid program from Managed Care to the new NY Medicaid Pharmacy Program (NYRx) (4/20/23)
- FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use (4/13/23)
- HIVinfo: Updates to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection (4/11/23)
- CEI: NYS Medical Providers—2023 CEI Annual Survey (4/11/23)
- FDA Approves First Over-the-Counter Naloxone Nasal Spray (3/29/23)
- HIVinfo: Updates to the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (3/23/23)
- NYSDOH Fact Sheet: Xylazine: What Clinicians Need to Know (3/9/23)
- CDC HAN: Increase in Extensively Drug-Resistant Shigellosis in the United States (3/2/23)
- NYSDOH Issues Commissioner Determination for the Use of Telemedicine to Ensure Continued Access to Life Saving Medication for New Yorkers Struggling with Mental Health and Opioid Use Disorder (2/1/23)
- HIVinfo: Updates to the Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission (1/31/23)
- CEI Hepatitis C Telehealth Toolkit (1/31/23)
- HIVinfo: Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV (1/18/23)
- CEI Congenital Syphilis Prevention Program Clinic Cards Available (1/17/23)
- NYSDOH AI: Congenital Syphilis Elimination Strategic Planning Group - Call for Membership Letter (1/9/23)
- FDA Approves New HIV Drug for Adults with Limited Treatment Options (12/22/22)
- NYSDOH AI: Health Equity Clinical Leadership Institute 12-Month Virtual Learning Collaborative (12/20/22)
- NYSDOH AI: Expansion of DBS for confirmatory HCV testing (12/6/22)
- New Videos from NIDA: At the Intersection: HIV & Substance Use Research (12/2/22)
- NYSDOH AI Dear Colleague Letter: No Out of Pocket Costs for PrEP (10/25/22)
- PrEP Aware Week Starts October 24th! (10/14/22)
- 06/05/2023: 9th Annual NYS Sexual Health Conference: Emerging Issues and Practice Updates
- 06/13/2023: CEI & PHPP: Care of Infants with Perinatal HIV Exposure in New York State
- 06/13/2023: HepCure & HCV and Drug User Health COE: Hepatitis C and HIV Coinfection
- 06/15/2023: HCV and Drug User Health COE: Strategies to Prevent Overdose in New York State: A Harm Reduction Framework
- 06/21/2023: HIV Primary Care and Prevention COE: Creating an LGBTQ-Affirming Practice
- 06/22/2023: HCV and Drug User Health COE: Buprenorphine Prescribing for Beginners
- 06/23/2023: HIV Primary Care and Prevention COE: 2023 New York State HIV Primary Care and Prevention Conference
- 06/29/2023: HCV and Drug User Health COE: Pain Management for People who Use Opioids
- 06/08/2023: MWAETC: 2023 HIV Clinical Update for Nurses Conference
- 06/12/2023: MA AETC: Beyond the Limits of HIV and Aging: Prevention, Treatment, and Resilience
- 06/12/2023: SCAETC: Health Equity TeleECHO Series Part 5: Retention to Care
- 06/14/2023: NEAETC: HIV & Oral Health Webinar Series Part 7: HPV, Sex, and Cancer
- 06/27/2023: SE AETC: Medical Case Management Trauma-Informed Approach to HIV Care
- 07/23/2023: IAS 2023, the 12th IAS Conference on HIV Science
- 09/06/2023: 2023 U.S. Conference on HIV/AIDS (USCHA)
- 10/11/2023: IDWeek 2023
- 10/26/2023: ANAC2023